secwatch.observer — SEC 8-K summary
======================================

Issuer:     Jazz Pharmaceuticals plc (JAZZ)
CIK:        0001232524
Form:       8-K
Filed at:   2024-01-08T23:59:59+00:00
Accession:  0001193125-24-003910
Event type: earnings
Sentiment:  positive
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Jazz Pharma reaffirms 2023 revenue guidance; sees 2024 double-digit growth for key drugs
--------------------------------------------------------------------------------

- Reaffirms 2023 total, neuroscience, and oncology revenue guidance range.
- Xywav, Epidiolex, and Rylaze expected to have combined double-digit revenue growth in 2024.
- High-sodium oxybate authorized generic royalty revenue expected to grow in 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1232524/000119312524003910/0001193125-24-003910-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1232524/000119312524003910/d636118d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-003910

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer